Edition:
United Kingdom

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

734.90INR
23 May 2018
Change (% chg)

Rs-5.20 (-0.70%)
Prev Close
Rs740.10
Open
Rs745.20
Day's High
Rs749.90
Day's Low
Rs733.10
Volume
744,439
Avg. Vol
1,577,552
52-wk High
Rs1,274.95
52-wk Low
Rs723.65

Select another date:

Thu, May 24 2018

BRIEF-Omeros Says Entered Into Settlement Agreement And Consent Judgment With Lupin Ltd and unit Lupin Pharmaceuticals - SEC Filing

* OMEROS SAYS ENTERED INTO SETTLEMENT AGREEMENT AND CONSENT JUDGMENT WITH LUPIN LTD, SUBSIDIARY LUPIN PHARMACEUTICALS - SEC FILING

UPDATE 2-India's Lupin expects U.S. drug pricing pressure to ease in 2019

* U.S. sales fall 21.1 pct; India sales up 14 pct (Adds management comments from conference call)

India's Lupin posts surprise Q4 loss on one-time charge

May 15 Lupin Ltd, India's second-largest drugmaker by revenue, reported a surprise loss in its fiscal fourth quarter on Tuesday, due to a one-time charge.

BRIEF-India's Lupin Gets FDA Approval For Generic Temovate Ointment, 0.05 Percent

* GETS FDA APPROVAL FOR GENERIC TEMOVATE OINTMENT, 0.05 PERCENT

BRIEF-India's Lupin Gets FDA Nod For Generic Xenazine Tablets, 12.5 Mg And 25 Mg

* SAYS CO RECEIVES FDA APPROVAL FOR GENERIC XENAZINE TABLETS, 12.5 MG AND 25 MG Source text - http://bit.ly/2qUd2T4 Further company coverage:

BRIEF-India's Lupin Gets Tentative U.S. FDA Nod For Generic Androgel, 1.62 Pct

* SAYS CO RECEIVES TENTATIVE FDA APPROVAL FOR GENERIC ANDROGEL, 1.62 PERCENT Source text - https://bit.ly/2HEhHk8 Further company coverage:

BRIEF-Lupin's Pithampur Unit 1 Facility Gets EIR From U.S. FDA

* SAYS PITHAMPUR UNIT 1 FACILITY RECEIVES ESTABLISHMENT INVESTIGATION REPORT (EIR) FROM US FDA

BRIEF-Lupin's Goa Facility Completes Successful U.K MHRA Inspection

* SAYS CO'S GOA FACILITY COMPLETES SUCCESSFUL UK MHRA INSPECTION

BRIEF-India's Lupin Says Pithampur Unit Cleared By Health Canada

* SAYS HEALTH CANADA MAINTAINED COMPLIANT RATING FOR UNIT 2 AT PITHAMPUR (INDORE) AND HAS ISSUED A REVISED ‘ESTABLISHMENT LICENSE’ Source text - https://bit.ly/2pW8cVF Further company coverage:

BRIEF-Lupin Launches Generic Clobex Spray, 0.05 Pct In U.S.

* SPRAY IS USED FOR TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS AFFECTING UP TO 20 PERCENT BODY SURFACE AREA IN PATIENTS 18 YEARS OF AGE OR OLDER Source text: http://bit.ly/2IeyRDQ Further company coverage:

Select another date: